There are 6 trial sites. Click on the link to learn more about each site.
The trial sites have been purposely chosen from the 4 sub-Saharan African regions (West, Central, East and Southern) to potentially target different circulating TB strains, different host genetic factors (e.g., regarding drug catabolism) and, overall, the African diversity of medical care delivery. Our intervention will also contribute to improve equity in patient’s rights for appropriate care management, whatever the resources and level of the local health system. Overall, DATURA’s results are expected to be generalisable to the whole sub-Saharan Africa.
The inclusion of one Asian site will further strengthen the generalisation potential of the intervention.
National Principal Investigators (PI)
Cambodia – Sovarannarith Samreth
Cameroon – Eric-Walter Pefure
Guinea – Boubacar Djelo Diallo
Uganda – Conrad Muzoora
Zambia – Suilanjoi Sivile
Mozambique – Bindiya Meggi